Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Treatment Protocol of Velaglucerase Alfa for Patients With Type 1 Gaucher Disease

This treatment has been approved for sale to the public.
Sponsor:
Information provided by (Responsible Party):
Shire
ClinicalTrials.gov Identifier:
NCT00954460
First received: August 5, 2009
Last updated: February 19, 2014
Last verified: February 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This treatment has been approved for sale to the public.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: No date given
No publications provided by Shire

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):